Business Wire

IL-FRISS

Share
FRISS Adds Niels Zijderveld as CCO to the Management Team

FRISS, the leading provider of AI-powered fraud and risk analytics for P&C insurers, welcomes Niels Zijderveld to their growing team. After over seven years working as sales director with Guidewire, Inc., the leading provider of core systems for P&C insurers, Niels will now lead the FRISS Sales and Marketing organizations as Chief Commercial Officer.

“Having Niels on our team will solidify our position as the market leader in fraud and risk analytics as we scale to meet our customers’ growing needs,” remarked FRISS CEO and Co-founder Jeroen Morrenhof. “Having helped countless customers find success while modernizing their core systems, Niels has a unique perspective on the increasing demands of today’s modern insurance carriers. While we of course look to continue growing our business, I am excited to do so under Niels’ careful guidance, knowing our customers’ needs will always be our number one priority.”

Niels joins the FRISS family at an exciting time when the need to help insurance become more honest has never been more important. Fraud accounts for 10-20% of an insurer’s claim costs, and hurts the average, honest consumer to the tune of $600-700 per year in unnecessarily high premiums.

“I’ve worked closely with FRISS over the past few years and they have always been a close and valuable partner for my clients,” shared Niels. “The unique fraud and risk analytics service FRISS provides is essential to safely enable Straight-Through-Processing, both in Claims and Underwriting. This in turns frees up time to service customers with insurer’s most valuable resource: their employees. The results FRISS has achieved with its customers both in quantitative and qualitative terms is spectacular. So of course, I’m excited to join the noble mission of FRISS and help honest customers – the vast majority of people just like you and me – receive fair premiums and the customer service they so deserve.”

Niels will oversee all commercial operations for FRISS, a fast-growing company in five global offices. In addition to ensuring the ongoing success of the company, he’ll keep an especially close eye on the FRISS culture: specifically, their core value of being a joy to do business with. Because just like the other 160 employees at FRISS, Niels knows that a best-in-class product only works as well as the people who create and use it.

ABOUT FRISS

FRISS is 100% focused on automated fraud and risk detection for P&C insurance companies worldwide. Their AI-powered detection solutions for underwriting, claims and SIU help 175+ insurers grow their business. FRISS detects fraud, mitigates risks and supports digital transformation. Insurers go live within 4 months, realize 10 times ROI and 80% increase in straight through processing of policy application and claims. FRISS solutions help lower loss ratios, enable profitable portfolio growth, and improve the customer experience. For more information, please visit www.friss.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Quectel Launches SP895BD-AP Smart Module, Powering the Next Generation of Intelligent IoT Applications5.1.2026 15:33:00 CET | Press release

Quectel Wireless Solutions, an end-to-end global IoT solutions provider, announced the official launch of its new-generation flagship smart module, the SP895BD-AP. Powered by the Qualcomm Dragonwing™ Q-8750 processor, the SP895BD-AP module boasts enhanced graphics processing capabilities, superior visual imaging effects, and advanced edge computing performance, meeting the requirements of high-end devices such as video conferencing systems, ultra-high-definition (UHD) displays, image synthesis equipment, computing power boards, smart retail terminals and smart home appliances. The SP895BD-AP redefines performance boundaries with its advanced hardware architecture. Powered by the Dragonwing Q-8750 processor built on a 3nm process, it features an 8-core high-performance Oryon™ CPU with a maximum frequency of 2×4.32 GHz + 6×3.53 GHz. Compared with the previous-generation (Series 8) chips, it achieves a 45% improvement in CPU performance and a 44% optimization in energy efficiency. This en

The Rock-It Company Expands Fine Art Logistics Capabilities of DIETL Through Acquisition of Several Strategic Infrastructure Services5.1.2026 15:00:00 CET | Press release

The acquisition strengthens DIETL’s fine art logistics operations through expanded access to specialized storage, handling and customs services. The Rock-It Company announced today that DIETL has acquired multiple fine art logistics specialists, strengthening its infrastructure and expanding access to specialized services across key U.S. art markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105175923/en/ The Rock-It Company Expands Fine Art Logistics Capabilities of DIETL Through Acquisition of Several Strategic Infrastructure Services The acquired companies include Delaware Freeport, Delaware National Art Company, Techno Export, and Registrar Technologies. Together, these businesses add depth across fine art storage, handling, packing, crating, installation support, customs brokerage, and technology-enabled logistics services, complementing DIETL’s existing operations. Delaware Freeport, a provider of high-security

TII Launches Falcon Reasoning: Best 7B AI Model Globally, Also Outperforms Larger Models5.1.2026 14:54:00 CET | Press release

Falcon H1R 7B Packs Advanced Reasoning into a Compact 7 Billion Parameter Model Optimized for Speed and Efficiency TII’s Latest AI Model Outperforms Larger Rivals from Microsoft, Alibaba, and NVIDIA on Key Benchmarks The Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), has announced the release of Falcon H1R 7B, a next-generation AI model that takes a significant step toward making advanced AI more accessible than ever, by delivering world-class reasoning performance in a compact, efficient, and openly available format. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105981339/en/ TII Launches Falcon Reasoning: Best 7B AI Model Globally, Also Outperforms Larger Models (Graphic: AETOSWire) With just 7 billion parameters, Falcon H1R 7B challenges and, in many cases, outperforms larger open-source AI models from around the world, including models fr

Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 14:00:00 CET | Press release

Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT TechnologyWorld's First Therapy Platform Simultaneously Solving Immune Rejection and Inheritance of Cellular Aging—The Major Hurdles of Existing Stem Cell TherapiesDrastically Improving Treatment Accessibility through the New Paradigm, ‘Patient-Initiated Clinical Trial™’, which Overcomes Existing Clinical Limitations Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evalu

HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release

Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye